Clinical Trial Update: ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

Phase 3 trial assessing AbbVie regimens ABT-450/r/ABT-267 with ABT-333 in treatment-naïve and treatment-experienced adults with chronic hepatitis C virus infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-267
• ABT-333 (ABT-333)
• ABT-450 (atazanavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED | Results posted: 2017-10-27